- wöchentlichErscheinungsrhythmus
- 30 mintypische Länge
- vor 16 Std.letzte Folge
In Vivo Podcasts is produced by the teams behind In Vivo, Scrip and Medtech Insight and covers biopharma and medtech in one place: the strategy, the science and the deals.
Every Tuesday, Strategic Intent is a candid, long-form conversation with one senior guest, including chief executives, R&D leaders, investors and regulators. Once a month, Proof of Concept goes deep on the science, from AI-designed drug discovery to the RNA therapeutics wave. And each month Scrip's Due Diligence follows the money: the M&A, licensing and financings redrawing the industry. Hosted by a rotating line-up of editors and reporters. Stay ahead with expert insight and intelligence.
Visit insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.
Folgen
Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both. Three and a half years ago, Circio ended its legacy oncolytic virus and ca
Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans
In this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different investments strategies, general market analysis across Europe and US, as well as growing therapeutic
Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck?
Disease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episode of Strategic Intent, Marion Webb (MedTech Insight) speaks with Dr. Soeren Mattke, research profes
Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown
Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics, discusses the company’s latest brand awareness push and what it
Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’
In this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts University School of Medicine, and Pamela Tanaerts, CMO and CSO at Medable, to discuss promising data f
Proof of Concept - Can AI Outrun the Next Outbreak?
What if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared Bauer, co-founder and CEO of Seek Labs, joins Proof of Concept to explain how his company's AI engine
Assessing the current dealmaking environment for psychedelic medicine.
Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP36
Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era
Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in years, spanning a specialty drug in interstitial lung disease, an
Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine
In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead topical GPX4 modulat
Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization
Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Ma
Strategic Intent: Evolving Requirements Of Life Sciences Leadership
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection
Proof Of Concept: How A Charity Bridges Lab And Clinic
Cancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, does something less obvious: it builds companies. This episode features Phil Masterson and Neil Jones, who run its ventures and drug dis
Strategic Intent: Beyond The Breakthrough - From Approval To Adoption
A medical device can work beautifully and still go nowhere. In this episode of Strategic Intent, Krishna Eluri sits down with Mark Saxton, U.S. CEO of Baird Medical, who has spent more than 25 years bringing first-of-their-kind procedural t
ZS On How AI is Reshaping The Patient's Approach to Care Delivery - a View From the US, China and Germany
A landmark three-country survey by the ZS consulting and technology firm , which shows the rapid trend towards patients' uptake of AI tools that empower them on their healthcare journeys. ZS’ Jon Roffman and Bhargav Mantha set the scene.
Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends
A videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath, EU, Europe
Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment
One in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's non-hormonal peptide platform - now FDA-cleared for human trials -
Strategic Intent: The Rise Of Mid-Cap Dealmakers
Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first co
Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies
On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks th
Proof of Concept - AI in Drug Discovery
In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation &
How ElevateBio Is Betting On Every Gene Editing Modality At Once
On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. El
Tonix’s Bet On Monoclonal Prevention Of Lyme Disease
Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceutica
The Yescarta Launch Examined
This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senio
Philips' Shez Partovi on increasing AI adoption, clinicians' attitudes and the hybrid care model
AI, Philips, Healthtech, Future Health Index 2026
GATC Health’s Derisq AI, A FICO Score for Drug Development
GATC Health wants to give drug developers a “FICO score” for clinical risk. In this episode, David Wild talks with GATC chief business officer Tyrone Lam about Derisq, an AI‑driven report that simulates human biology to predict a drug candi
Jeremy Levin’s Call to Action to Save American Biotech
A conversation with Jeremy Levin — physician-scientist, former Teva CEO, and author of Biotech and the Balance — on why America's biotech industry is at a strategic inflection point. Levin examines the forces undermining innovation: short-t
Decoding Cell Stress at Soley Therapeutics
Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform
Kurma’s €215m Fund And What It Says About European Funding Environment
Kurma Partners has closed BioFund IV at €215m — its largest fund to date, but roughly €35m short of its initial target. For partner Amanda Gett-Chaperot, that gap is more than a fundraising footnote: it points to a structural problem that h
Podcast: Inside Arcutis with CEO Frank Watanabe
Arcutis Biotherapeutics' CEO Frank Watanabe joins In Vivo’s David Wild to talk about building a patient‑first culture and turning a three‑person startup into a commercial‑stage immunodermatology company. He explains how Zoryve (roflumilast)
